Clinical Trial Update: Efficacy and Safety of TF002 in Cutaneous Mastocytosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TF002 shows efficacy and safety signals in cutaneous mastocytosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Mastocytosis

Drugs mentioned

• TF002

Snippet

Sponsor: JADO Technologies GmbH | Conditions: Cutaneous Mastocytosis | Phase 2 | Status: COMPLETED